APTOF— Aptose Biosciences Inc.

Aptose Biosciences Inc. (APS:CA) Shareholder/Analyst Call Prepared Remarks Transcript

Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement

Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arrangement with Hanmi Pharmaceutical

Aptose Biosciences Announces Amendment to Arrangement Agreement and Details of Postponed Special Meeting of Shareholders

Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC

Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations

Aptose Biosciences agrees to be acquired by Hanmi Pharmaceutical subsidiary for C$2.41 per share

Aptose Biosciences GAAP EPS of -$2.01